Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2

Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2

In the BOLERO-2 trial, everolimus (EVE), an inhibitor of mammalian target of rapamycin, demonstrated significant clinical benefit with an acceptable safety profile when administered with exemestane (EXE) in postmenopausal women with hormone receptor-positive (HR(+)) advanced breast cancer. We report...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Hope S. Rugo, Kathleen I. Pritchard, Michael Gnant, Shinzaburo Noguchi, Martine Piccart, G. N. Hortobagyi, José Baselga, Alejandra Perez, Matthias Geberth, Tibor Csőszi, E. Chouinard, Vichien Srimuninnimit, Puttisak Puttawibul, Janice F. Eakle, Wentao Feng, H. Bauly, Mona El-Hashimy, T Taran, Howard A. Burris
التنسيق: Artigo
اللغة:الإنجليزية
منشور في: 2014
الوصول للمادة أونلاين:https://doi.org/10.1093/annonc/mdu009
http://www.annalsofoncology.org/article/S0923753419364981/pdf
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

الانترنت

https://doi.org/10.1093/annonc/mdu009
http://www.annalsofoncology.org/article/S0923753419364981/pdf

مواد مشابهة